Lipitor Cost in New Hampshire 2026: Atorvastatin Prices, Insurance, and Medicaid Coverage

Prescription access and medication affordability image for Lipitor Cost in New Hampshire 2026: Atorvastatin Prices, Insurance, and Medicaid Coverage

At a glance

  • Generic cash price (NH retail, 2026) / ~$10/month
  • Brand Lipitor list price (Pfizer) / ~$280/month
  • NH Medicaid covers Lipitor brand / No; generic atorvastatin covered
  • Compounded atorvastatin (503A pharmacy, NH) / Legal and available
  • Telehealth prescribing legal in NH / Yes
  • Standard dose / 10 to 80 mg oral tablet once daily
  • Pfizer savings card (commercially insured) / As low as $4/fill
  • GoodRx lowest NH price (July 2025 data) / ~$9, $12 for 30 tablets
  • FDA approval year / 1996

What Does Atorvastatin Actually Cost in New Hampshire Right Now?

Generic atorvastatin is one of the most affordable prescription drugs in New Hampshire. Cash-pay patients at major retail pharmacies pay roughly $10 per month for a 30-day supply of the 10 mg, 20 mg, or 40 mg tablet in 2026. The 80 mg dose may run slightly higher at some chains but rarely exceeds $15 without a discount card applied.

Brand-name Lipitor carries Pfizer's published list price of approximately $280 per month. That figure appears on pharmacy benefit invoices, but very few patients pay it out of pocket. Commercially insured patients with Pfizer's Lipitor savings card can pay as little as $4 per fill. Patients without insurance can use free discount programs through GoodRx, RxSaver, or NeedyMeds to access generic prices in the $9 to $12 range at Walgreens, CVS, Walmart, and Hannaford locations throughout New Hampshire.

Atorvastatin was approved by the FDA in 1996 and lost patent exclusivity in 2011. Generic entry after patent loss consistently drives prices below $15 per month for statins in most U.S. markets. The clinical evidence for atorvastatin is extensive. ASCOT-LLA (N=10,305) demonstrated that atorvastatin 10 mg reduced fatal and non-fatal myocardial infarction by 36% versus placebo over a median 3.3 years in hypertensive patients without prior coronary disease (P<0.0001) [1]. That trial, published in The Lancet in 2003, helped establish atorvastatin as a first-line agent in cardiovascular prevention guidelines worldwide.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "Statin therapy is recommended for primary prevention of ASCVD in patients with LDL-C levels 70 to 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher." [2] Generic atorvastatin is the statin most commonly used to fulfill that recommendation in U.S. outpatient practice.

The ACC/AHA 2018 Cholesterol Guideline further specifies high-intensity statin therapy (atorvastatin 40 to 80 mg daily) for patients with established ASCVD or LDL-C above 190 mg/dL [3]. At the 80 mg dose, monthly cash cost at New Hampshire pharmacies remains below $15 with any major discount card.

Does New Hampshire Medicaid Cover Lipitor or Generic Atorvastatin?

New Hampshire Medicaid (NH Medicaid, administered through the NH Department of Health and Human Services) does not cover brand-name Lipitor. Generic atorvastatin, however, appears on the New Hampshire Medicaid preferred drug list and is covered as a standard benefit for eligible enrollees with qualifying diagnoses such as hyperlipidemia or established atherosclerotic cardiovascular disease (ASCVD).

Medicaid enrollees in NH pay zero to minimal cost-sharing for generic atorvastatin when it is prescribed for a covered indication. The prescriber does not need to obtain prior authorization for generic atorvastatin at standard doses (10 to 80 mg) in most clinical scenarios. Requesting brand-name Lipitor under Medicaid would require a prior authorization demonstrating medical necessity for the brand over generic, a request that is almost never approved given therapeutic equivalence.

FDA's Orange Book confirms that all currently marketed generic atorvastatin calcium tablets carry an AB therapeutic equivalence rating to Lipitor, meaning substitution is considered clinically appropriate [4]. NH Medicaid's formulary decisions align with this rating.

Patients who do not qualify for NH Medicaid but have low income may access the New Hampshire Prescription Drug Affordability Program or federally qualified health center (FQHC) sliding-scale pricing. The federal 340B Drug Pricing Program allows participating NH health centers to dispense generic atorvastatin at deeply reduced costs to uninsured and underinsured patients. The Health Resources and Services Administration oversees 340B eligibility and lists participating NH sites publicly.

The USPSTF issued a Grade B recommendation in 2022 supporting preventive statin use for adults aged 40 to 75 years with one or more CVD risk factors and a calculated 10-year CVD event risk of 10% or greater [5]. Under the Affordable Care Act, Grade B USPSTF recommendations require most commercial plans to cover the preventive service without cost-sharing, which in practice means most commercial insurers in NH cover generic atorvastatin with a $0 or low-tier copay for qualifying patients.

How Does Private Insurance Cover Atorvastatin in New Hampshire?

Most commercial health insurance plans sold in New Hampshire, including those offered through the NH Health Insurance Marketplace, cover generic atorvastatin on Tier 1 or Tier 2 of their formularies. Tier 1 generic copays typically range from $0 to $15 per 30-day fill. A 90-day mail-order supply frequently costs the same as two 30-day retail fills, reducing annual out-of-pocket cost considerably.

Brand-name Lipitor is placed on Tier 3 or Tier 4 by most NH plan formularies in 2026. At Tier 3, the patient may owe $40 to $80 per fill before deductible. At Tier 4, costs can reach $100 or more per fill without supplemental assistance. Pfizer's Lipitor savings card caps the patient's cost at $4 per fill for commercially insured patients who meet eligibility criteria. Full Pfizer savings card terms are listed at the Lipitor official site, and the card cannot be combined with government insurance including Medicaid or Medicare Part D.

Medicare Part D plans in New Hampshire place generic atorvastatin on Tier 1 in virtually all standard Part D formularies. The Medicare Plan Finder allows NH beneficiaries to compare exact atorvastatin costs by plan. Under the Inflation Reduction Act, Medicare Part D enrollees face a $2,000 annual out-of-pocket cap starting in 2025, which limits total statin spending for high-utilization patients [6].

Employer-sponsored plans in NH follow similar tier structures. Large self-insured employers often use pharmacy benefit managers (PBMs) such as Express Scripts or CVS Caremark, which negotiate generic atorvastatin rebates that further reduce net plan cost. Employees rarely pay more than $10 per fill for generic atorvastatin under these arrangements.

A practical decision framework for NH patients choosing between brand and generic:

  1. If your plan covers generic atorvastatin at Tier 1 and your prescriber has written for atorvastatin (not Lipitor specifically), fill the generic. Cost: $0, $15/month.
  2. If your prescriber wrote "Lipitor" and your pharmacy is billing brand at Tier 3, 4, ask for a generic substitution. All NH pharmacies may substitute AB-rated generics per NH RSA 318:47-d unless the prescriber writes "dispense as written."
  3. If you are uninsured, use GoodRx or RxSaver coupons for generic atorvastatin. Cost: $9, $12/month at most NH chains.
  4. If you have commercial insurance and prefer the Lipitor brand for any clinical reason, apply the Pfizer savings card. Cost: $4/fill.
  5. If you are on Medicaid, the generic is covered. Do not pay cash.

Is Compounded Atorvastatin Legal in New Hampshire?

Compounded atorvastatin is legally available in New Hampshire through state-licensed 503A compounding pharmacies. 503A refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional patient-specific compounding by licensed pharmacists operating within a state's pharmacy practice framework.

New Hampshire's pharmacy practice act, administered by the NH Board of Pharmacy, permits 503A pharmacies to compound atorvastatin for individual patients when a valid patient-specific prescription exists and a documented clinical rationale supports the compounded preparation over commercially available tablets. Common clinical rationales include documented allergenicity to tablet excipients (lactose, talc, or certain dyes found in commercial formulations) or a need for a dose not available commercially (for example, 5 mg for elderly patients requiring a lower starting dose than the commercially available 10 mg tablet).

The FDA's guidance on compounding under 503A notes that compounding of a drug that is essentially a copy of an approved commercial product is generally impermissible unless the prescriber documents a clinical difference [7]. Because atorvastatin tablets are commercially available in 10, 20, 40, and 80 mg strengths, a 503A pharmacy in NH may not simply compound a 20 mg atorvastatin capsule as a cost-saving substitute without that documented clinical justification.

When valid, compounded atorvastatin through a NH 503A pharmacy can cost $0 to minimal dispensing fee, particularly when the compounding pharmacy operates within an integrated health system or federally qualified health center that uses 340B drug pricing. Outside those systems, compounded atorvastatin from a private 503A pharmacy may carry a preparation fee of $20 to $60 per month depending on the formulation complexity, which is higher than the $10 cash price for commercial generic tablets.

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, cannot compound atorvastatin unless it appears on the FDA's 503B drug shortage list. Atorvastatin is not currently on that list as of mid-2025 [8]. Patients should verify their NH compounding pharmacy's license type before assuming a bulk-compounded preparation is legally dispensed.

Can I Get a Lipitor or Atorvastatin Prescription via Telehealth in New Hampshire?

Telehealth prescribing of atorvastatin is fully legal in New Hampshire. NH enacted permanent telehealth prescribing flexibilities that allow a licensed clinician to prescribe non-controlled medications, including atorvastatin, after a synchronous audio-video visit that satisfies the standard of care for history-taking and clinical decision-making.

The prescriber does not need to conduct an in-person physical examination before initiating atorvastatin via telehealth, provided the visit includes a thorough medication and medical history, discussion of relevant labs (particularly a fasting lipid panel and liver function tests), and documentation of a qualifying indication such as hyperlipidemia or ASCVD risk reduction. The NH Telehealth Law (RSA 167:4-d) governs parity in Medicaid telehealth reimbursement, and most commercial NH plans follow similar parity rules under state law [9].

Patients who initiate atorvastatin via telehealth should obtain a baseline fasting lipid panel before or shortly after starting therapy. The ACC/AHA 2018 cholesterol guideline recommends a repeat fasting lipid panel 4 to 12 weeks after statin initiation to confirm LDL-C response [3]. A 50% or greater reduction in LDL-C is the expected response for high-intensity atorvastatin (40 to 80 mg). Telehealth follow-up visits can accommodate this monitoring without requiring an in-person visit for the majority of patients who tolerate atorvastatin without side effects.

Telehealth platforms operating in NH must hold a valid NH prescriber license or work with a NH-licensed supervising physician. Prescriptions generated during a telehealth visit are transmitted electronically to any NH retail or mail-order pharmacy. The patient pays the same price at the pharmacy regardless of whether the prescription originated from an in-person or telehealth visit.

What Are the Clinical Reasons NH Prescribers Choose Atorvastatin Over Other Statins?

Atorvastatin's pharmacokinetic profile makes it the most frequently prescribed statin in U.S. outpatient practice. It is a high-intensity statin at 40 and 80 mg doses, meaning it achieves LDL-C reductions of 50% or more. Only rosuvastatin matches it at high-intensity dosing, and atorvastatin has substantially more long-term outcome data behind it.

The ASCOT-LLA trial [1] used atorvastatin 10 mg daily in a primary prevention population and demonstrated the 36% relative risk reduction in major cardiovascular events noted earlier. The TNT trial (N=10,001) compared atorvastatin 80 mg versus atorvastatin 10 mg in stable coronary disease and found that intensive therapy further reduced major cardiovascular events by 22% [10]. These data underpin guideline recommendations for high-intensity dosing in high-risk patients.

Hepatotoxicity concerns with statins are often overstated. A 2006 review in the American Journal of Cardiology found that clinically significant statin-induced liver injury is rare, occurring in fewer than 1 per 100,000 patient-years of exposure [11]. Routine liver function monitoring is no longer recommended by the FDA for patients on stable statin therapy. The FDA label update in 2012 removed the requirement for routine periodic liver enzyme testing [12].

Myopathy is the side effect of greatest clinical concern. Statin-associated muscle symptoms (SAMS) occur in approximately 5 to 10% of patients in observational studies, though randomized trials suggest a lower incidence of about 1 to 3% attributable to the drug rather than nocebo effect. The SAMSON trial (N=200) used a blinded n-of-1 design and found that 90% of statin-associated muscle symptom burden was attributable to nocebo effect rather than pharmacological drug action [13]. Clinicians in NH who encounter patients reluctant to take atorvastatin due to muscle concerns can reference this finding during shared decision-making.

Drug interactions of practical relevance in NH primary care include clarithromycin, which inhibits CYP3A4 and can raise atorvastatin plasma levels significantly. The FDA label for atorvastatin recommends dose reduction or temporary suspension during courses of strong CYP3A4 inhibitors [4]. Grapefruit juice also inhibits intestinal CYP3A4 and can raise atorvastatin area under the curve, though the clinical significance at standard doses is modest.

Practical Tips for Reducing Atorvastatin Costs in New Hampshire

Patients in New Hampshire have several concrete options for reducing their atorvastatin spending to near zero in 2026.

First, ask for a 90-day supply. Most NH pharmacies and all major mail-order pharmacies dispense 90-day supplies. Many commercial plans price a 90-day generic at the same cost as two 30-day fills, saving one copay per quarter. For a $10/month generic, a 90-day supply may cost $20 rather than $30.

Second, use a free discount card. GoodRx, RxSaver, and NeedyMeds list current prices at every NH pharmacy. Prices vary by pharmacy by $2 to $5 per fill, and the app shows which NH location is cheapest on any given day. Walmart's $4 generic program covers atorvastatin 10, 20, and 40 mg at NH Walmart pharmacy locations.

Third, check the Pfizer Patient Assistance Program. Uninsured or underinsured patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level) may receive Lipitor or generic atorvastatin at no cost through Pfizer's RxPathways program. NeedyMeds maintains a database of manufacturer assistance programs and state pharmaceutical assistance programs relevant to NH residents [14].

Fourth, verify NH Medicaid eligibility. Atorvastatin is covered on the NH Medicaid preferred drug list with minimal cost-sharing. Patients within 138% of the federal poverty level may qualify for NH Medicaid and pay nothing for their statin [15].

Fifth, consider a telehealth prescriber for ongoing management. Telehealth visits for chronic medication management are typically $0, $75 per visit at most platforms and are frequently covered by NH commercial plans under parity law. The prescriber can also order a lipid panel at a low-cost lab (LabCorp and Quest both operate NH draw sites) and transmit the prescription electronically to the NH pharmacy of the patient's choice.

Frequently asked questions

How much does Lipitor cost in New Hampshire?
Brand-name Lipitor costs approximately $280 per month at list price at New Hampshire pharmacies in 2026. Generic atorvastatin costs roughly $10 per month with a discount card such as GoodRx or RxSaver. Commercially insured patients using the Pfizer Lipitor savings card pay as little as $4 per fill.
Does New Hampshire Medicaid cover Lipitor?
New Hampshire Medicaid does not cover brand-name Lipitor. It does cover generic atorvastatin on its preferred drug list for eligible enrollees with qualifying diagnoses including hyperlipidemia and ASCVD. Prior authorization is not typically required for generic atorvastatin at standard doses.
Is compounded atorvastatin legal in New Hampshire?
Yes. A state-licensed 503A compounding pharmacy in New Hampshire may compound atorvastatin for an individual patient when a valid patient-specific prescription exists and a documented clinical rationale supports the compounded preparation over commercially available tablets. 503B bulk compounding of atorvastatin is not currently permitted because atorvastatin is not on the FDA 503B drug shortage list.
Can I get Lipitor via telehealth in New Hampshire?
Yes. New Hampshire law permits licensed clinicians to prescribe non-controlled medications including atorvastatin via synchronous audio-video telehealth visits. The prescriber must take an adequate medical and medication history and document a qualifying indication. The prescription is transmitted electronically to any NH retail or mail-order pharmacy.
Which insurance plans cover Lipitor in New Hampshire?
Most commercial plans, Medicare Part D plans, and NH Medicaid cover generic atorvastatin on Tier 1 of their formularies with a $0 to $15 copay. Brand Lipitor is typically on Tier 3 or Tier 4 of commercial formularies. Pfizer's savings card reduces brand Lipitor cost to $4 per fill for commercially insured patients who are not on Medicare or Medicaid.
What's the cheapest way to get Lipitor in New Hampshire?
The cheapest option for most NH patients is generic atorvastatin with a free GoodRx or RxSaver discount card, costing $9 to $12 per month at retail pharmacies. Walmart's $4 generic program covers atorvastatin at NH Walmart locations. Medicaid-eligible patients pay zero. Pfizer's RxPathways patient assistance program provides free medication to uninsured patients meeting income criteria.
Are there New Hampshire Lipitor discount programs?
Yes. Free discount card programs (GoodRx, RxSaver, NeedyMeds) reduce generic atorvastatin to under $12/month at NH pharmacies. Pfizer's Lipitor savings card covers commercially insured patients. Pfizer's RxPathways program covers uninsured or underinsured patients meeting income criteria. NH Medicaid covers generic atorvastatin for eligible enrollees. The federal 340B program reduces costs at participating NH health centers.
How does the Pfizer savings card work in New Hampshire?
Pfizer's Lipitor savings card is available to commercially insured patients in New Hampshire who are not enrolled in Medicare, Medicaid, or any other government health program. The card caps the patient's out-of-pocket cost at $4 per fill. It is applied at the pharmacy counter and cannot be combined with insurance benefits directly; the patient pays the $4 co-pay and the card covers the remainder up to the program maximum.

References

  1. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial, Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158. https://pubmed.ncbi.nlm.nih.gov/12686036/
  2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678
  3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
  4. U.S. Food and Drug Administration. Lipitor (atorvastatin calcium) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf
  5. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Events in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. https://pubmed.ncbi.nlm.nih.gov/35997723/
  6. Cubanski J, Neuman T. Explaining the Prescription Drug Provisions in the Inflation Reduction Act. KFF. 2022. https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
  7. U.S. Food and Drug Administration. Compounding Laws and Policies. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
  8. U.S. Food and Drug Administration. 503B Bulksubstances List. FDA. https://www.fda.gov/drugs/human-drug-compounding/503b-outsourcing-facilities
  9. New Hampshire Department of Health and Human Services. Telehealth. DHHS. https://www.dhhs.nh.gov/programs-services/medicaid/telehealth
  10. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435. https://pubmed.ncbi.nlm.nih.gov/15755765/
  11. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C-81C. https://pubmed.ncbi.nlm.nih.gov/16949495/
  12. U.S. Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. FDA. 2012. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs
  13. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182-2184. https://pubmed.ncbi.nlm.nih.gov/33186537/
  14. NeedyMeds. Patient Assistance Programs. NeedyMeds. https://www.needymeds.org/
  15. Centers for Medicare and Medicaid Services. Medicaid Eligibility. CMS. https://www.medicaid.gov/medicaid/eligibility/index.html